WO No.10 Week 2

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 4

TO KNOW THE DIAGNOSIS AND MANAGEMENT OF EMERGENCY SKIN

DISORDERS AND ITS REFERRAL SYSTEM AND PROGNOSIS OF THE DISEASE

Dermatologic problems represent about 15%–20% of visits to family physicians and


emergency departments. It is often a challenge for a primary care provider to differentiate
mundane skin ailments from more serious, life-threatening conditions that require immediate
intervention. The purpose of this article is to highlight some dermatologic emergencies.
Staphylococcal toxic shock syndrome: This toxin-mediated disease is characterized by
rapid onset of generalized erythema with desquamation, fever, hypotension and potential
mutisystem failure. The illness occurs in the setting of Staphylococcus aureus infection, for
example in women using menstrual tampons of high absorbency, or in patients with
superficial skin or surgical wound infections. S. aureusproduces exotoxins, which induce
massive cytokine secretion by T cells; fever, hypotension and multi-organ failure result. After
a 2–3 day prodrome period of malaise, patients typically present with fever, chills, nausea
and abdominal pain. A diffuse erythematous, nonpruritic, maculopapular or petechial rash
ensues, with subsequent desquamation. The rash initially appears on the trunk and spreads
peripherally to the palms and soles. Multi-system involvement includes arrhythmias, hepatic
and renal failure, disseminated intravascular coagulation and acute respiratory distress
syndrome.
Management: Aggressive supportive management is required to treat hypotension and
potential multi-organ failure. Inciting factors should be removed. Once culture specimens are
obtained, treatment with a β-lactamase-resistant anti-staphylococcal antibiotic is
recommended.
Angioedema: Characterized by well-circumscribed areas of edema caused by increased
vascular permeability, this condition affects mostly the skin, and the gastrointestinal and
respiratory tracts. Patients typically present with acute subcutaneous swelling, usually of the
face, extremities or genitalia.
A generalized anaphylactic reaction may occur, which is potentially fatal if the upper airway
is compromised. Urticaria can be associated with angioedema in 50% of cases; the
angioedema is usually nonpruritic but burning. Although often idiopathic, angioedema can be
induced by medications, allergens (e.g., food) or physical agents (e.g., vibration, cold).
Typically, 10%–25% of cases are due to angiotensin-converting-enzyme (ACE) inhibitor
therapy, occurring in 1–2 per 1000 new users. Penicillins, NSAIDs and radiographic contrast
media are other potential triggers. Angioedema can occur as a result of C1 esterase inhibitor
(C1INH) deficiency. Two rare but well-described categories exist: hereditary angioedema,
which is transmitted in autosomal-dominant fashion, and acquired angioedema, which can be
associated with autoimmune disorders and B-cell lymphoproliferative malignant disease.
Management: Treatment is largely supportive. Airway patency must be ensured if the
respiratory system is involved. Cool, moist compresses and antihistamines can be used to
control local burning. Referral to an allergy specialist for appropriate investigations should be
considered. Avoidance of known triggers, such as associated medications, is paramount. ACE
inhibitors are contraindicated in patients with C1INH deficiency. Attenuated androgens
danazol and stanozolol increase the amount of active C1INH and are used for the prevention
of hereditary angioedema. An algorithm for the diagnosis and management of hereditary
angioedema was recently published.1
Exfoliative erythroderma: This is a generalized scaly erythematous skin eruption involving
more than 90% of the cutaneous surface. Although many cases are idiopathic, it can be
associated with a diverse range of underlying dermatoses, including eczema, psoriasis, drug
reaction (e.g., allopurinol, calcium-channel blockers, anticonvulsants and lithium), cutaneous
T-cell lymphoma or leukemia, pityriasis rubra pilaris, paraneoplastic syndrome and
dermatomyositis. Pruritus is usually the initial symptom, and malaise and fever may
subsequently develop owing to excessive vasodilation. Fluid and protein loss through the skin
can lead to life-threatening hypotension, electrolyte imbalance, congestive heart failure and
enteropathy. In a study involving 91 patients with erythroderma, the disease-specific
mortality was 18%;253% of the cases were associated with exacerbation of an existing
dermatosis, which underscores the need for a thorough history and skin examination to
identify a potential underlying skin condition.
Management: The cause should be determined and, if a drug reaction is suspected, the
offending medication stopped. Skin biopsies can be obtained to help establish the diagnosis.
Supportive therapy includes hospital admission, proper hydration, nutrition, electrolyte and
cardiac monitoring, and temperature support. Skin care involves the use of emollients and
compresses as well as topical corticosteroid therapy and antihistamines for pruritus.
Antibiotic therapy should be administered if signs of infection develop.
Necrotizing fasciitis: This rapidly spreading infection of the deep fascia can cause necrosis
of the subcutaneous tissues. Type II necrotizing fasciitis is caused by group A streptococci,
whereas mixed anaerobes, gram-negative aerobic bacilli and enterococci are implicated in
type I. The organisms can be introduced through minor cuts, burns, blunt trauma or surgical
procedures. Risk factors include diabetes mellitus, peripheral vascular disease and
immunosuppression. The first cutaneous manifestation of streptococcal necrotizing fasciitis is
diffuse swelling of the affected skin area followed by the development of bullae, which
rapidly become burgundy in colour. Without prompt treatment, the infection may develop
into frank cutaneous gangrene. Shock and organ failure can ensue and portend a poor
prognosis. When skin necrosis is not obvious, diagnosis of necrotizing fasciitis must be
suspected if there are signs of severe sepsis or some of the following local symptoms and
signs: severe pain, indurated edema, skin hyperesthesia, crepitation, muscle weakness and
foul-smelling exudate.
Management: Early recognition, aggressive management of sepsis and surgical débridement
of the necrotic tissue are essential for effective treatment of necrotizing fasciitis.
Antistreptococcal antimicrobial therapy should be administered; however, if the causal agents
cannot be definitively identified, the patient should be given broad-spectrum antibiotics, as
dictated by the clinical picture.
Meningococcemia: Neisseria meningitidis is a leading cause of meningitis and septicemia
among North American youth. The incidence of invasive meningococcal disease is about 1.1
cases per 100 000, with the peak incidence at 6–12 months of age, when protective antibodies
have not yet developed. The classic presentation of meningococcemia is the abrupt onset of
maculopapular or petechial rash and flu-like symptoms, including fever, chills, malaise and
disorientation. Over several hours, the disease may rapidly progress to purpura, disseminated
intravascular coagulation, shock and death.
Management: Any febrile patient with a petechial rash should be suspected of having
meningococcemia and treated promptly after blood cultures are obtained. Besides supportive
management, therapy with a third-generation cephalosporin (e.g., ceftriaxone) or intravenous
penicillin G therapy are the treatments of choice. Chloramphenicol may be used for patients
allergic to penicillin.
Stevens–Johnson syndrome and toxic epidermal necrolysis: These conditions represent a
spectrum of drug-induced or idiopathic mucocutaneous reaction patterns, characterized by
skin tenderness, erythema, epidermal necrosis and desquamation. The pathogenesis is thought
to involve an impaired capacity to detoxify intermediate drug metabolites and genetic
susceptibility. Common medications responsible for Stevens–Johnson syndrome (SJS) and
toxic epidermal necrolysis (TEN) include sulfonamides, anticonvulsants, allopurinol and
NSAIDs. Drug administration typically precedes the rash by 1–3 weeks. Patients may present
with a prodrome of fever, stinging eyes and pain on swallowing, followed by the
development of dusky erythematous macules that progress to flaccid blisters. Two or more
mucous membranes are usually involved, with erythema and erosions of buccal, genital and
ocular mucosa. Severe ophthalmic involvement may lead to permanent scarring and
blindness. Epidermal detachment is common, which may lead to massive fluid loss and
electrolyte imbalance. Less than 10% of the epidermis sloughs off in SJS and more than 30%
in TEN. These conditions are potentially life-threatening because of their multisystem
involvement and skin-barrier breakdown. Epithelial loss results in vulnerability to bacterial
and fungal infections and predisposes patients to septicemia and severe fluid loss. Mortality
ranges from 5% in SJS to 30% in TEN.
Management: SJS and TEN should be managed by an experienced physician. Supportive
measures include identification and removal of the offending medication, admission to a burn
unit if necessary, intravenous fluid administration, maintenance of electrolyte and
temperature homeostasis, and ophthalmologic assessment in case of ocular involvement. Skin
care consists of proper wound dressings, oral hygiene (i.e., chlorhexidine rinses),
antihistamine and topical corticosteroid therapy for pruritus, and antimicrobial therapy in
cases of superinfection due to skin-barrier breakdown. Some centres use high doses of
immunoglobulin intravenously as mainstay therapy for TEN; however, more evidence of its
effectiveness is needed.
Rocky Mountain spotted fever: This condition is potentially life-threatening and is most
commonly introduced to humans through tick bites carrying the Rickettsia rickettsii parasite.
Canadian vectors of R. rickettsii include Dermacentor variabilis (dog tick) in eastern Canada
and Dermacentor andersoni (wood tick) in western Canada. Rocky Mounted spotted fever is
associated with a mortality of 3%– 7% among treated patients and 30%– 70% among those
not treated promptly or adequately. In about 60% of cases, patients present with a triad of
fever, headache and rash following a tick bite. The classic rash with this condition appears
within the first 2 weeks on the wrists and ankles and rapidly spreads to the palms and soles
and eventually to the trunk and face. Purpuric macules and papules can be observed.
Multiorgan involvement may lead to a variety of symptoms, which makes the diagnosis
challenging. Complications of Rocky Mounted spotted fever include myocarditis and
cardiogenic shock, peripheral edema due to hepatic failure and hypoalbuminemia, acute renal
failure, altered mental status, seizures or coma, meningismus and disseminated intravascular
coagulation.
Management: Besides symptomatic support, appropriate antibiotic treatment should be
initiated immediately when this condition is suspected. Doxycycline is the drug of choice and
should be continued for at least 3 days after fever subsides and until clinical improvement.
The tick should be removed if embedded in the skin at the time of presentation.

You might also like